Pharma BD Deal Intelligence
Outcome grade pending — assessed 5 years post-close.
Full analysis, sources & comparables →Sanofi taps Kali for rights to clinical trispecific for immunology: Deals Report. Sanofi obtained exclusive worldwide rights to Kali Therapeutics' KT501 for…
Sanofi returns to T-cell engager territory with $1.2B pact for phase 1-stage trispecific. The deal reflects Sanofi's continued push into immune-depletion…
Released May 18, 2026: KT502, a high-potency CD19 x CD3 bispecific T-cell engager, earned an oral presentation at EULAR 2026 (London, June 4). The release…
Source summaries from our enrichment pipeline; follow links for originals.
All 8 sources with sentiment breakdown →
Sanofi obtained exclusive worldwide rights to Kali Therapeutics' KT501, a Phase 1 tri-specific T-cell engager targeting CD3/CD19/BCMA for B-cell autoimmune diseases. Kali receives $180M upfront/near-term plus up to $1.05B in milestones and tiered royalties. Deal reflects Sanofi's continued push into immune-depletion strategies for autoimmune disease.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Sanofi SA / Kali Therapeutics, Inc. (this deal) | 2026 | $1.2B | — |
| Sanofi SA / Regeneron Pharmaceuticals, Inc. | 2007 | $1.0B | 97 |
| Sanofi SA / Synthelabo S.A. | 1998 | $11.0B | 84 |
| Sanofi SA / Genzyme Corporation | 2011 | $20.1B | 84 |
| Sanofi SA / Amunix Pharmaceuticals Inc. | 2021 | $1.2B | 76 |
| Sanofi SA / Genzyme Corporation | 2010 | $18.5B | 75 |
| Sanofi SA / Translate Bio Inc. | 2018 | $805M | 73 |
← Browse all deals · How we score deals
More: 2026 deals · Sanofi SA deals · Immunology deals